Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.30 |
| ▸ | NOS1 | P29475 | 3/20 | 0.30 |
| ▸ | NOS2 | P35228 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22558141 | 1.00 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1TSHRCASP1 | |
| SCHEMBL6004083 | 1.00 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1TSHRCASP1 | |
| SCHEMBL2447831 | 1.00 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1TSHRCASP1 | |
| SCHEMBL5378424 | 1.00 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1TSHRCASP1 | |
| SCHEMBL3988343 | 0.94 | TRIM24 (0.39) | TRIM24TRIM33ALDH1A1TSHR | |
| SCHEMBL7577171 | 0.82 | — | — | |
| SCHEMBL502191 | 0.67 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1TSHRCASP1 | |
| SCHEMBL1332943 | 0.67 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1TSHRCASP1 | |
| SCHEMBL6797157 | 0.67 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1TSHRCASP1 | |
| SCHEMBL365601 | 0.67 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063243-A | Aromatic compound, preparation method, intermediate, pharmaceutical composition and application thereof | 上海旭成医药科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | claimed |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-1966221-A1 | PYRIMIDO- [4, 5-]-OXAZINES FOR USE AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071966-A1 | PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-8592010-B2 | Optical compensation films | MERCK PATENT GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-8017603-B2 | Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| US-20100208181-A1 | OPTICAL COMPENSATION FILMS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-7749997-B2 | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors | ASTRAZENECA AB (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7511110-B2 | Crosslinkable polyorganosiloxane compositions | WACKER CHEMIE AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966221-A1 | PYRIMIDO- [4, 5-]-OXAZINES FOR USE AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-7285368-B2 | Polymerizable ester having sulfonamide structure, polymer, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| WO-2007071966-A1 | PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20060135689-A1 | Crosslinkable polyorganosiloxane compositions | WACKER CHEMIE GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20050003303-A1 | Polymerizable ester having sulfonamide structure, polymer, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-0872484-B1 | ORGANOSILICON COMPOUNDS, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT | CHISSO CORP (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-5993690-A | Organosilicon compound, liquid crystal composition, and liquid-crystal display element | CHISSO CORPORATION (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0872484-A1 | ORGANOSILICON COMPOUNDS, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT | CHISSO CORPORATION (JP) | 1998-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | TRIM24 4356/4885TRIM33 4359/4885ALDH1A1 38/4885 |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | DGAT1, DGAT2, ACAT2 | TRIM24 3707/4885TRIM33 4549/4885ALDH1A1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.